The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ICML 2025 | The promise of non-covalent BTK inhibitors, including pirtobrutinib, in MCL
Krish Patel, MD, Sarah Cannon Research Institute, Nashville, TN, briefly discusses the value of non-covalent BTK inhibitors, namely pirtobrutinib, in the mantle cell lymphoma (MCL) treatment landscape, and comments on how these agents may impact the field. This interview took place during the 18th International Conference on Malignant Lymphoma (18-ICML) in Lugano, Switzerland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Yeah, so we’ve had a non-covalent BTK inhibitor approved in mantle cell now for a little while, pirtobrutinib. We’re seeing others in that space as well. I think what we’re all really excited for and awaiting is a randomized study that demonstrates what the safety and efficacy of pirtobrutinib looks like in comparison to covalent BTK inhibitors. So that’s the BRUIN MCL-321 study...
Yeah, so we’ve had a non-covalent BTK inhibitor approved in mantle cell now for a little while, pirtobrutinib. We’re seeing others in that space as well. I think what we’re all really excited for and awaiting is a randomized study that demonstrates what the safety and efficacy of pirtobrutinib looks like in comparison to covalent BTK inhibitors. So that’s the BRUIN MCL-321 study. So I think this is really going to help us to define what is the appropriate place in sequencing for a non-covalent inhibitor. Should we be using these before covalent inhibitors or should we continue to use covalent inhibitors and then use pirtobrutinib in later lines. And then of course we’ll see data from other non-covalent inhibitors and hopefully soon BTK degraders in that same area as well.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
